Democrats have introduced a bill that would allow anyone over age 50 to buy into Medicare; an FDA advisory panel has endorsed a ketamine-like depression drug; and the EPA is set to limit the amount of manmade chemicals allowed in drinking water.
On Wednesday, House and Senate Democrats introduced legislation that would allow anyone over age 50 to buy into Medicare. According to POLITICO, the bill sponsors said that the plan will pay for itself with the premiums from new enrollees and more of the money collected would pay for patient care because of “the relative lack of overhead and profit requirements in Medicare compared to the private insurance market.”
An FDA advisory panel has endorsed the experimental medication esketamine for depression. Determining that the benefits outweigh the risks, the panel voted 15-2 in favor of the ketamine-like drug. If the drug, manufactured by Johnson & Johnson, is approved, it would be the first major depression treatment approved in decades, according to STAT News. Some experts have expressed concern that the drug has a high potential for abuse because ketamine is often abused.
The EPA is expected to announce today that it will limit how much toxic chemicals from cookware and carpeting are allowed in drinking water, reported Reuters. The group of chemicals, known as PFAS, have been linked to cancer, liver and thyroid damage, and other health effects. HHS’ Agency for Toxic Substances and Disease Registry said the risk level for exposure to these chemicals should be at least 7 to 10 times lower than the threshold currently recommended by the EPA.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More